Sinovac Biotech (SVA) Short Interest Ratio & Short Volume

Short interest is the volume of Sinovac Biotech shares that have been sold short but have not yet been covered or closed out. As of January 15th, traders have sold 186,100 shares of SVA short. 0.69% of Sinovac Biotech's shares are currently sold short. Learn More on Sinovac Biotech's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.69% of Sinovac Biotech's floating shares are currently sold short.

Sinovac Biotech saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 186,100 shares, a drop of 0.3% from the previous total of 186,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Sinovac Biotech currently has issued a total of 0 shares. Some of Sinovac Biotech's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Sinovac Biotech currently has a public float of 26,890,000 shares.

0.69% of Sinovac Biotech's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Sinovac Biotech: Context Therapeutics Inc. (0.08%), Grifols, S.A. (2.32%), LAVA Therapeutics (1.50%), Mainz Biomed (2.34%), NLS Pharmaceutics Ltd. (1.54%), Pharvaris (0.10%), Procaps Group S.A. (0.03%), Qilian International Holding Group Limited (0.07%), American Oncology Network, Inc. (1.02%), Collegium Pharmaceutical, Inc. (23.28%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Advanced Micro Devices, Inc. ($8.74 billion), S&P Global Inc. ($7.90 billion), Charter Communications, Inc. ($5.88 billion), Lucid Group, Inc. ($3.75 billion), Palo Alto Networks, Inc. ($3.44 billion), Wayfair Inc. ($2.88 billion), Rivian Automotive, Inc. ($2.60 billion), Zscaler, Inc. ($1.86 billion), Match Group, Inc. ($1.79 billion), and Carnival Co. & plc ($1.72 billion). View all of the most shorted stocks.

Short selling SVA is an investing strategy that aims to generate trading profit from Sinovac Biotech as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Sinovac Biotech occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SVA, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SVA, twice per month. The most recent reporting period available is January, 15 2022.